Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05388734 | Shared Decision Making on Care Pathways and CAMs: A Pilot Study | unknown | N/A | 100 | University Hospital, GrenobleOTHER | 1 | May 16, 2023 | clinicaltrials |
| NCT05860374 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors | unknown | Early Phase 1 | 20 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | May 16, 2023 | clinicaltrials |
| NCT05858762 | Artificial Intelligence for Automated Diagnosis of Breast Cancer(AICAMAMMELLA) | unknown | — | 200 | Regina Elena Cancer InstituteOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT05857111 | Effectiveness Validation of CELBREA® in Symptomatic Women or With Diagnostic Doubt of Breast Pathology (DETECT-BH)(DETECT-BH) | unknown | — | 255 | Jose Ignacio SánchezOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT03484000 | The ONE-MIND Study: Evaluating the Efficacy of Online Mindfulness-Based Cancer Recovery During Chemotherapy Treatment | unknown | N/A | 178 | University of CalgaryOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT05288686 | Use of Superparamagnetic Iron Oxide (SPIO) in Sentinel Lymph Node Detection for Breast Cancer | unknown | N/A | 282 | The University of Hong KongOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT05574686 | Telemonitoring Hypertension and Breast Cancer | unknown | N/A | 40 | University of Mississippi Medical CenterOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT04877860 | Pain Treatment in a Breast Cancer Population. PaiNEd Study.(PaiNEd) | unknown | N/A | 72 | Universidad de GranadaOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05354882 | Interventional Study on DEterminants and Factors of Physical ACtivity After Treatments in Oncology(DEFACTO2) | unknown | N/A | 150 | Université Sorbonne Paris NordOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05826197 | Prediction of Axillary Lymph Node Metastasis Status in Breast Cancer Based on PET/CT Radiomics | unknown | — | 100 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 0 | May 9, 2023 | clinicaltrials |
| NCT04293276 | Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer(DAP-Her-01) | unknown | Phase 2 | 41 | Henan Cancer HospitalOTHER_GOV | 1 | May 6, 2023 | clinicaltrials |
| NCT05831553 | TIP in Patients Affected by Metastatic TNBC(TIP) | unknown | — | 100 | Fondazione per la Medicina PersonalizzataOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05842148 | Quality of Life After Conservative Oncoplastic Surgery in Breast Cancer Patients (IRONY: lIfe afteR ONcoplastic surgerY)(IRONY) | unknown | — | 250 | Campus Bio-Medico UniversityOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05846997 | Use of INnovative and Micro-INvasive TEchniques for the Early Identification of Breast Cancer Patients Benefitting From Neo-adjuvant Therapy(INTENT) | unknown | — | 40 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05836246 | The Development of Quantitative Ultrasound Imaging Software Platform | unknown | — | 196 | Seoul National University Bundang HospitalOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT05400954 | Association of Silicone Breast Implants With Overall Wellbeingand Auto-immune Diseases(AREOLA-B) | unknown | — | 15,000 | The Netherlands Cancer InstituteOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT05834686 | HER2 Expression of CTC to Predict Response in HER2-positive Advanced Breast Cancer Patients Treated With ADC | unknown | — | 50 | Beijing 302 HospitalOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT05834699 | HER2 Expression of CTC to Predict Response in HER2-low Advanced Breast Cancer Patients Treated With ADC | unknown | — | 50 | Beijing 302 HospitalOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT05833802 | Computation Prediction of Drug Response Based on Omics Data | unknown | — | 25 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05833919 | Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients | unknown | Phase 2 | 122 | Consorzio OncotechOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05448963 | Pilot Study of Single-port Robot-assisted Nipple-sparing Mastectomy | unknown | N/A | 30 | Chang Gung Memorial HospitalOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT05807516 | Single-cell RNAseq Breast Cancer(SCRBC) | unknown | — | 20 | Regina Elena Cancer InstituteOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT05828238 | Positron Emission Tomograph(PET) Imaging Explores the Role of SF-DEVD-2 in Monitoring Tumor Efficacy | unknown | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT04014283 | Prevention of Female Cancers by Optimization of Selenium Levels in the Organism.(SELINA) | unknown | N/A | 7,000 | Read-Gene S.A.OTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05170087 | Radiomic Analysis for Predicting Treatment Response and Clinical Outcomes in Malignancies | unknown | — | 1,200 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT03578380 | Supermicrosurgery for Breast Cancer Survivors With Lymphedema. | unknown | N/A | 100 | Sykehuset TelemarkOTHER_GOV | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05033769 | Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer(AIRE) | unknown | Phase 4 | 82 | Institut fuer FrauengesundheitOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05036005 | Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)(NeoON) | unknown | Phase 4 | 108 | Institut fuer FrauengesundheitOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05177432 | Quadratic Phenotypic Optimisation Platform (QPOP) Utilisation to Enhance Selection of Patient Therapy Through Patient Derived Organoids in Breast Cancer(QUEST) | unknown | Phase 1 | 26 | National University Hospital, SingaporeOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05258383 | Personalized Estimation of Doses Delivered During Image Guided Radiation Therapy Tests(ELISA) | unknown | — | 320 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05814224 | Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA(MAGNETIC1) | unknown | N/A | 164 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT04733417 | A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer. | unknown | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05773391 | Mechanism Exploration of Anti-HER-2 Small-molecule Tyrosine Kinase Inhibitor-related Diarrhea and Establishment of Prevention and Treatment Model(Measure) | unknown | N/A | 100 | Sun Yat-sen UniversityOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT04303741 | A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC | unknown | Phase 2 | 46 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05556200 | A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs | unknown | Phase 2 | 58 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05809024 | Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy | unknown | Phase 4 | 100 | Yongsheng WangOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05806671 | Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05758948 | Detection of Germline and Somatic Pathogenic Variants in Patients With de Novo Metastatic Breast Cancer | unknown | — | 101 | Hellenic Cooperative Oncology GroupOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT05746728 | Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer | unknown | Phase 1 / Phase 2 | 45 | Huihua XiongOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT05800197 | Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia(NEMO) | unknown | — | 300 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT05800756 | Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer | unknown | Phase 2 | 30 | Yantai Yuhuangding HospitalOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT04821570 | To Assess Immunogenicity of Coronavirus Disease 2019 (COVID-19) Vaccine in Cancer Patients Receiving Cancer Treatment(CANINE) | unknown | — | 500 | University of Kansas Medical CenterOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05594082 | Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast Cancer | unknown | — | 150 | Fudan UniversityOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05792410 | A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer. | unknown | Phase 1 / Phase 2 | 300 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Mar 31, 2023 | clinicaltrials |
| NCT05737446 | Oxygen Partial Pressure After Breast Cancer Surgery | unknown | — | 60 | Umeå UniversityOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05790096 | Effectiveness and Safety Study of Filgrastine® in Patientes With Breast Cancer Treated With Myelotoxic Chemotherapy | unknown | Phase 3 | 60 | Blau Farmaceutica S.A.INDUSTRY | 0 | Mar 29, 2023 | clinicaltrials |
| NCT05764941 | Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer | unknown | — | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT00412022 | HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.(HOBOE) | unknown | Phase 3 | 1,294 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT00431704 | VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer(VinCaT) | unknown | Phase 2 | 39 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT04953377 | PFMT Educational Intervention for Patients With Advancer Breast Cancer | unknown | N/A | 42 | OnkologikoaOTHER | 1 | Mar 24, 2023 | clinicaltrials |
Data updated 24 days agoSource updated May 16, 2023source: clinicaltrials